Last updated on November 2017

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)


Brief description of study

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

Detailed Study Description

The goal of the OPTIMAL study is to gradually reduce anti-rejection medication(s) in liver transplant recipients over a period of time until the medication(s) are stopped. This is called immunosuppression withdrawal.

As part of the OPTIMAL study, investigators will also do blood and liver biopsy tests to see whether they can identify common markers of immune systems that are able to tolerate transplanted livers without immunosuppressive medications. Identification of these markers and tests will help transplant doctors predict whether it is safe to decrease or stop anti-rejection medication(s) for future liver transplant recipients.

In general, study visits will consist of a brief physical exam, and some visits will also include questionnaires as well as blood, urine, stool (fecal), and liver biopsy collections.

In total, participation may last between 3.5 and 6 years.

For more information, visit www.optimalstudy.org

Clinical Study Identifier: TX2962

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sharon Blaschka, MSN, NP-C

University of California, San Francisco Medical Center
San Francisco, CA USA
  Connect »

Patrice Al-Saden, RN

Northwestern Memorial University
Chicago, IL USA
  Connect »

Victor Luu

Massachusetts General Hospital – Transplant Center
Boston, MA USA
  Connect »

Stephanie Dermont

UPMC Montefiore, 7 South 
Pittsburgh, PA USA
  Connect »

Claudia Musat

Columbia Medical Center
New York, NY USA
  Connect »

Barbara Lilly

Baylor Research Institute
Dallas, TX USA
  Connect »